
FDA approves Alzheimer’s drug shown to moderately slow cognitive decline in early stages of the disease
The Food and Drug Administration on Friday approved a new Alzheimer’s disease treatment that moderately slows cognitive decline in people with early-stage disease. The drug, called Leqembi, was developed by …
Read More